FeesSafety
Pluang+

Evolution Petroleum posts mixed Q4 results with adjusted loss but revenue beats estimates

Company Fundamentals
15 Sep 2026
Gordon Thompson
View Source
Neutral
Evolution Petroleum posts mixed Q4 results with adjusted loss but revenue beats estimates

Evolution Petroleum reported a fiscal Q4 adjusted loss of $0.02 per share, missing the $0.01 estimate, but revenue rose 15% to $24.21 million, beating expectations. GAAP net income was $4.61 million, up from $3.41 million a year earlier, helped by unrealized gains on derivatives. Adjusted EBITDA doubled sequentially to $6.52 million but remained 24% below last year’s quarter. The company’s balance sheet shows $56.5 million in debt and liquidity supported by credit availability. Investors should note the contrast between positive GAAP earnings and weaker adjusted operating results.

Evolution Petroleum's Q4 2026 earnings report provides context for energy sector performance. For readers following energy stocks, here is Pluang's market snapshot as of Sep 16, 2026 02:01 WIB: Among 30 priced US energy stocks, 24 rose and 6 fell today. Notably, Occidental Petroleum Corporation (OXY) increased by 2.74% to USD 63.47, Diamondback Energy Inc (FANG) rose 2.66% to USD 211.20, and Ecopetrol SA (EC) climbed 2.60% to USD 18.20.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
1 hour ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
1 hour ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
Tether's Mining Development Kit gains support from 15 mining firms to unify Bitcoin mining tools.

Tether's Mining Development Kit gains support from 15 mining firms to unify Bitcoin mining tools.

Tether has announced that 15 mining operators, ASIC manufacturers, and mining pools have committed to integrating with its open-source Mining Development Kit (MDK). The MDK aims to solve compatibility issues in Bitcoin mining by providing a unified f...

Protocol Fundamentals
Bullish
4 hours ago
U.S. Bitcoin ETFs saw $6.4B inflows since August, outpacing corporate buys amid rising producer prices and rate hike bets.

U.S. Bitcoin ETFs saw $6.4B inflows since August, outpacing corporate buys amid rising producer prices and rate hike bets.

Since August, U.S. spot Bitcoin exchange-traded funds (ETFs) have attracted about $6.4 billion in net inflows, significantly more than the roughly $1.5 billion in Bitcoin purchases by corporate treasuries. BlackRock’s IBIT ETF led with around $6 bill...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App